Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Sachin Chaudhary
Associate Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(15)
Kenneth Knox
Mutual work: 8 Publications
Collaboration Details
Michael Grandner
Mutual work: 1 Publication
Collaboration Details
Christian Bime
Mutual work: 2 Publications
Collaboration Details
Joshua Malo
Mutual work: 1 Publication
Collaboration Details
Bhupinder Natt
Mutual work: 2 Proposals﹒7 Publications﹒2 Grants
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(22)
An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)
Active
·
2024
·
$395K
·
External
Principal Investigator (PI)
pulmonary fibrosis,
long-term safety,
efficacy,
idiopathic pulmonary fibrosis
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associate
Active
·
2024
·
$811.7K / $270.6K
·
External
Principal Investigator (PI)
clinical trials,
systemic sclerosis
A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
Active
·
2024
·
$664.8K / $221.6K
·
External
Principal Investigator (PI)
pulmonary fibrosis,
clinical trial,
efficacy,
safety,
dose-ranging
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bi 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (Pf-ilds)
Active
·
2023
·
$1.4M / $272K
·
External
Principal Investigator (PI)
clinical trials,
interstitial lung diseases,
drug efficacy,
patient safety,
progressive fibrosing
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Active
·
2023
·
$473.7K / $118.4K
·
External
Principal Investigator (PI)
idiopathic pulmonary fibrosis,
inhaled treprostinil,
subjects,
open-label
Page 1 of 5
Previous page
Next page
Publications
(25)
Recent
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
2023
idiopathic pulmonary fibrosis,
autotaxin inhibitor,
lung function,
clinical trials,
isabela 1 and 2
Interstitial lung disease progression after genomic usual interstitial pneumonia testing
2022
lung disease progression,
genomic testing,
interstitial lung disease,
pneumonia,
genomic analysis
Uncovering the Epidemiology of Idiopathic Pulmonary Fibrosis in the Veterans Affairs Health System
2022
pulmonary fibrosis,
epidemiology,
veterans,
health system
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection PRECISIONS) clinical trial
2022
ipf treatment,
clinical trial design,
precision medicine
Prophylaxis in Lung Transplant Recipients
2022
prophylaxis,
lung transplant,
recipients,
immunosuppression,
infection control
Comparison of the Filtration Efficiency of Different Face Masks Against Aerosols
2021
face masks,
filtration efficiency,
aerosols,
comparison,
healthcare
Title: THE IMPACT OF THE ENVISIA GENOMIC CLASSIFIER IN THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH INTERSTITIAL LUNG DISEASE
2021
genomic,
lung disease,
diagnosis,
management,
impact
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial
2021
antimicrobial therapy,
idiopathic pulmonary fibrosis,
clinical trial
The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis
2021
genomic classifier,
diagnosis,
management,
idiopathic pulmonary fibrosis,
impact
SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic Individuals on the University of Arizona Campus
2021
covid-19,
antigen testing,
symptomatic,
asymptomatic,
university campus
